- Home
- Publications
- Publication Search
- Publication Details
Title
Research progress of mTOR inhibitors
Authors
Keywords
mTOR inhibitor, mTOR, Anticancer, Drug design
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 208, Issue -, Pages 112820
Publisher
Elsevier BV
Online
2020-09-13
DOI
10.1016/j.ejmech.2020.112820
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy both in vivo and vitro
- (2020) Fangxiang Mu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression
- (2020) B. Wang et al. Clinical & Translational Oncology
- mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain
- (2020) Songyeon Choi et al. NEUROSCIENCE LETTERS
- Effects of mTOR inhibitors on neuropathic pain revealed by optical imaging of the insular cortex in rats
- (2020) Kyeongmin Kim et al. BRAIN RESEARCH
- Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
- (2020) Kazuki Kuroshima et al. CANCER SCIENCE
- EGCG protects vascular endothelial cells from oxidative stress-induced damage by targeting the autophagy-dependent PI3K-AKT-mTOR pathway
- (2020) Jiao Meng et al. Annals of Translational Medicine
- mTOR: A Cellular Regulator Interface in Health and Disease
- (2019) Fahd Boutouja et al. Cells
- Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
- (2019) Angelica Benavides-Serrato et al. PLoS One
- A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
- (2019) Pauline T. Lukey et al. EUROPEAN RESPIRATORY JOURNAL
- A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
- (2019) Hye Joung Choi et al. GYNECOLOGIC ONCOLOGY
- Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
- (2019) Hang Zhao et al. OncoTargets and Therapy
- Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
- (2019) Mi Na Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner
- (2019) Ying Zhang et al. PHYTOMEDICINE
- A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
- (2019) Edward Wolin et al. PLoS One
- Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety
- (2019) Chiara Borsari et al. ACS Medicinal Chemistry Letters
- Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
- (2019) Maria M. Rubinstein et al. CANCER
- Resveratrol: a review of plant sources, synthesis, stability, modification and food application
- (2019) Bingren Tian et al. JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
- Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells
- (2019) Sameer S. Chopra et al. Cell Systems
- CC-223 inhibits human head and neck squamous cell carcinoma cell growth
- (2018) Jun-ying Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inhibition of FOXO1 transcription factor in primary human adipocytes mimics the insulin-resistant state of type 2 diabetes
- (2018) Meenu R. Rajan et al. BIOCHEMICAL JOURNAL
- Cryo-EM structure of human mTOR complex 2
- (2018) Xizi Chen et al. CELL RESEARCH
- New Insights Into the Role of mTOR Signaling in the Cardiovascular System
- (2018) Sebastiano Sciarretta et al. CIRCULATION RESEARCH
- A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
- (2018) Johanna C. Bendell et al. CLINICAL CANCER RESEARCH
- Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases
- (2018) Karolina Pierzynowska et al. METABOLIC BRAIN DISEASE
- Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors
- (2018) Althaf Shaik et al. MOLECULES
- Assessment of drug–drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase
- (2018) Zeen Tong et al. XENOBIOTICA
- Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
- (2018) Martin Fenner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms
- (2017) Mohd Rehan JOURNAL OF CELLULAR BIOCHEMISTRY
- 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
- (2017) Florent Beaufils et al. JOURNAL OF MEDICINAL CHEMISTRY
- Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
- (2017) Rajen Mody et al. LANCET ONCOLOGY
- Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
- (2017) Ramon Salazar et al. ONCOLOGIST
- Invitro Evaluation of Torin2 and 2, 6-Dihydroxyacetophenone in Colorectal Cancer Therapy
- (2017) Ankita Awasthi et al. PATHOLOGY & ONCOLOGY RESEARCH
- Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation
- (2017) Noha M. Shawky et al. PHARMACOLOGICAL RESEARCH
- Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
- (2017) Angelica Benavides-Serrato et al. PLoS One
- CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo
- (2017) Zichen Xie et al. PLoS One
- Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo
- (2017) Lan Zheng et al. Oncotarget
- The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
- (2017) Zuquan Xiong et al. Oncotarget
- Rapamycin-insensitive companion of mTOR ( RICTOR ) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 Inhibition
- (2016) S. T. Kim et al. ANNALS OF ONCOLOGY
- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
- (2016) Emmanuel Seront et al. BJU INTERNATIONAL
- A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
- (2016) Joaquin Mateo et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
- (2016) Josep María del Campo et al. GYNECOLOGIC ONCOLOGY
- Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
- (2016) Günter Emons et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
- (2016) Jessica L. Geiger et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
- (2016) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
- (2016) M. C. Smith et al. MOLECULAR CANCER THERAPEUTICS
- mTORC2 Puts Its Shoulder to Krebs’ Wheel
- (2016) Sebastian I. Arriola Apelo et al. MOLECULAR CELL
- mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1
- (2016) Joseph G. Moloughney et al. MOLECULAR CELL
- (−)-Epigallocatechin-3-gallate induces apoptosis in human pancreatic cancer cells via PTEN
- (2016) SHI LIU et al. Molecular Medicine Reports
- An evolutionarily conserved pathway controls proteasome homeostasis
- (2016) Adrien Rousseau et al. NATURE
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
- (2016) Helma Freitag et al. NEUROENDOCRINOLOGY
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors
- (2016) Oren J. Becher et al. PEDIATRIC BLOOD & CANCER
- Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair
- (2016) Durga Udayakumar et al. RADIATION RESEARCH
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
- (2016) I. Ben-Sahra et al. SCIENCE
- Genistein-induced LKB1–AMPK activation inhibits senescence of VSMC through autophagy induction
- (2016) Kyung Young Lee et al. VASCULAR PHARMACOLOGY
- Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
- (2016) Timothy P. Heffron et al. ACS Medicinal Chemistry Letters
- A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
- (2016) Andrew D.J. Pearson et al. Oncotarget
- RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
- (2016) Nneha Sakre et al. Oncotarget
- Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
- (2016) Haeseong Park et al. Oncotarget
- The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models
- (2016) Yun-Rong Zhu et al. Oncotarget
- Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
- (2016) Eva Juengel et al. Oncotarget
- 4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1
- (2016) Huirong Yang et al. Protein & Cell
- Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
- (2016) David N. Franz et al. PLoS One
- Toward rapamycin analog (rapalog)-based precision cancer therapy
- (2015) Ling-hua Meng et al. ACTA PHARMACOLOGICA SINICA
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
- (2015) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
- (2015) D. S. Mortensen et al. MOLECULAR CANCER THERAPEUTICS
- Unknown
- (2015) Azhar Hussain et al. MOLECULAR MEDICINE
- The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth
- (2015) CONGREN WANG et al. ONCOLOGY REPORTS
- Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
- (2015) Giovanni Luca Gravina et al. TUMOR BIOLOGY
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
- (2015) P. Liu et al. Cancer Discovery
- Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis
- (2015) Samira M. Sadowski et al. Oncotarget
- The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
- (2015) Carolina Simioni et al. Oncotarget
- OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo
- (2015) Xiao Zhi et al. Oncotarget
- A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
- (2015) Guang Yang et al. Cell Reports
- mTORC2 Regulates Cardiac Response to Stress by Inhibiting MST1
- (2015) Sebastiano Sciarretta et al. Cell Reports
- Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
- (2015) Carolina Simioni et al. Oncotarget
- Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines
- (2014) Yasufumi Katanasaka et al. CANCER LETTERS
- High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma
- (2014) Maqbool Ahmed et al. CARCINOGENESIS
- Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
- (2014) Daliah Tsoref et al. GYNECOLOGIC ONCOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
- (2014) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models
- (2014) Giovanni Luca Gravina et al. PROSTATE
- Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
- (2013) N Colombo et al. BRITISH JOURNAL OF CANCER
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- (2013) Q. Liu et al. CANCER RESEARCH
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- (2013) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- mTORC2 phosphorylates protein kinase Cζ to regulate its stability and activity
- (2013) Xin Li et al. EMBO REPORTS
- Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration
- (2013) Monica Dalal et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2
- (2013) Fan Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology
- (2013) Venus Thomanetz et al. JOURNAL OF CELL BIOLOGY
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
- (2013) Craig S. Takeuchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma
- (2013) MIN HU et al. ONCOLOGY REPORTS
- Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins
- (2013) K. K. Hanson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
- (2013) A. M. Robitaille et al. SCIENCE
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
- (2012) Carmine Settembre et al. EMBO JOURNAL
- Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
- (2012) Hajime Asahina et al. INVESTIGATIONAL NEW DRUGS
- VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
- (2012) S. Hart et al. MOLECULAR CANCER THERAPEUTICS
- mTOR Complex 2 Regulates Proper Turnover of Insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8
- (2012) Sung Jin Kim et al. MOLECULAR CELL
- PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12
- (2012) Xiaoqing Gan et al. NATURE CELL BIOLOGY
- Sulforaphane Induces Cell Cycle Arrest and Apoptosis in Acute Lymphoblastic Leukemia Cells
- (2012) Koramit Suppipat et al. PLoS One
- NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
- (2012) Emmanouil Fokas et al. Radiation Oncology
- Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor
- (2011) Glenn S. Van Aller et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
- (2011) Christoph M. Dehnhardt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
- (2011) Timothy R. Peterson et al. CELL
- Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
- (2011) K.-Y. Chang et al. CLINICAL CANCER RESEARCH
- The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells
- (2011) G. L. Gravina et al. ENDOCRINE-RELATED CANCER
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
- (2011) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
- (2011) Joungmok Kim et al. NATURE CELL BIOLOGY
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines
- (2011) Wolfgang Glienke et al. TUMOR BIOLOGY
- Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
- (2010) Timothy P. Heffron et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
- (2010) Aranapakam M. Venkatesan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-α and mTOR for the treatment of breast cancer
- (2010) Nan Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
- (2010) K. Yu et al. CANCER RESEARCH
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- A Ras Signaling Complex Controls the RasC-TORC2 Pathway and Directed Cell Migration
- (2010) Pascale G. Charest et al. DEVELOPMENTAL CELL
- A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF -TRCP
- (2010) B. Zhao et al. GENES & DEVELOPMENT
- Resveratrol Inhibits mTOR Signaling by Promoting the Interaction between mTOR and DEPTOR
- (2010) Meilian Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Novel Coronary Smooth Muscle Cell Proliferation Inhibitor Biolimus A9 in Healthy Individuals
- (2010) Wolfgang Steudel et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
- (2010) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
- (2010) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Stereoselective Synthesis of an Active Metabolite of the Potent PI3 Kinase Inhibitor PKI-179
- (2010) Zecheng Chen et al. JOURNAL OF ORGANIC CHEMISTRY
- Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
- (2010) Diana Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
- (2010) Calvin K. Yip et al. MOLECULAR CELL
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
- (2010) Katrin Düvel et al. MOLECULAR CELL
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1
- (2010) T. Kantidakis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
- (2009) J.-C. Soria et al. ANNALS OF ONCOLOGY
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR
- (2009) Keith A. Menear et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability
- (2009) David J. Richard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K
- (2009) Jeroen C. Verheijen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
- (2009) R Diaz et al. BRITISH JOURNAL OF CANCER
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging
- (2009) Rogerio M. Castilho et al. Cell Stem Cell
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402
- (2009) Christoph M. Dehnhardt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
- (2009) Nao Hosokawa et al. MOLECULAR BIOLOGY OF THE CELL
- ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
- (2009) Chang Hwa Jung et al. MOLECULAR BIOLOGY OF THE CELL
- EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells
- (2009) Chi-Hung Huang et al. MOLECULAR NUTRITION & FOOD RESEARCH
- Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity
- (2009) Teather J. Sundstrom et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
- (2009) Hui H. Zhang et al. PLoS One
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
- (2008) Q. Xue et al. CANCER RESEARCH
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- SKAR Links Pre-mRNA Splicing to mTOR/S6K1-Mediated Enhanced Translation Efficiency of Spliced mRNAs
- (2008) Xiaoju Max Ma et al. CELL
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth
- (2008) Thomas Porstmann et al. Cell Metabolism
- Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration
- (2008) Pazit Polak et al. Cell Metabolism
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Regulation of TORC1 by Rag GTPases in nutrient response
- (2008) Eunjung Kim et al. NATURE CELL BIOLOGY
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
- (2008) Y. Sancak et al. SCIENCE
- Curcumin as “Curecumin”: From kitchen to clinic
- (2007) Ajay Goel et al. BIOCHEMICAL PHARMACOLOGY
- Targeting phosphoinositide 3-kinase—Moving towards therapy
- (2007) Romina Marone et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More